BioNotebook: After selling to Actelion, entrepreneur Tullman starts new company, and Revance, Dicerna, UniQure file for IPOs
This article was originally published in Scrip
Executive Summary
Steve Tullman, the serial biopharma entrepreneur who sold companies to Actelion, Allergan and Cephalon in the past few years, is starting a new company, Alexar Therapeutics. Malvern, Pennsylvania-based Alexar is being formed with $21.5 million in financing raised by Mr Tullman’s firm NeXeption. In September, another Tullman company, Ceptaris Therapeutics, was sold to Actelion for $250 million.